Author

A. Aimon

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 3 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:drug response / drug discovery· 3 Assay:protein structure· 2 Research Focus:protein structure prediction· 2 Organism:virus· 2 Approach:statistical model· 1 Assay:structural biology· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

A. Douangamath· 4 shared D. FearoniD· 3 shared F. von DelftiD· 3 shared L. Dunnett· 3 shared T. Krojer· 3 shared A. Dias· 2 shared E. Resnick· 2 shared J. Brandao-Neto· 2 shared

Activity by Year

2018-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBiochemistry

A. Douangamath

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Structure, Mechanism and Crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase

J. A. Newman, A. Douangamath, S. Yazdani, Y. Yosaatmadja, A. Aimon, J. Brandao-Neto, L. Dunnett, T. Gorrie-Stone, R. Skyner, D. Fearon, M. Schapira, F. von Delft, O. Gileadi

This study presents crystal structures of SARS-CoV-2 NSP13 and identifies druggable pockets, revealing potential targets for antiviral drug development through fragment screening.

Nature Communications · Aug 11, 2021Peer-reviewedBiochemistry

Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking

M. Schuller, G. J. Correy, S. Gahbauer, D. Fearon, T. Wu, R. E. Diaz, I. D. Young, L. Carvalho Martins, D. H. Smith, U. Schulze-Gahmen, T. W. Owens, I. Deshpande, G. E. Merz, A. C. Thwin, J. T. Biel, , Smi

The paper identifies new chemical fragments binding to the SARS-CoV-2 Nsp3 macrodomain through crystallographic screening and computational docking, validating their binding with biophysical techniques.

bioRxiv · Nov 24, 2020Biochemistry

Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease

A. Douangamath, D. Fearon, P. Gehrtz, T. Krojer, P. Lukacik, C. D. Owen, E. Resnick, C. Strain-Damerell, A. aimon, P. Abranyi-Balogh, J. Brandao-Neto, A. Carberry, G. Davison, A. Dias, T. D. Downes, , M. A. Walsh

The paper identifies fragment hits against SARS-CoV-2 main protease using crystallography and mass spectrometry, revealing structural insights for drug design.

bioRxiv · May 27, 2020Biophysics

Rapid covalent-probe discovery by electrophile fragment screening

e. resnick, A. Bradley, J. Gan, A. Douangamath, T. Krojer, R. Sethi, A. Aimon, G. Amitai, D. Belini, J. Bennett, M. Fairhead, O. Fedorov, P. P. Geurink, J. Guo, A. Plotnikov, , N. London

This study develops a method for discovering covalent probes using electrophile fragment screening and identifies selective inhibitors for OTUB2 and NUDT7.

bioRxiv · Oct 14, 2018Biochemistry